

1 **Biofabrication of multiplexed electrochemical immunosensors for** 2 **simultaneous detection of clinical biomarkers in complex fluids**

3 Sanjay S. Timilsina^{1,+}, Mohanraj Ramasamy^{1,2,3}, Nolan Durr¹, Rushdy Ahmad¹, Pawan Jolly¹, Donald E.
4 Ingber^{1,4,5,*}

5 ¹*Wyss Institute for Biologically Inspired Engineering, Harvard University, 02115, USA,*

6 ²*Department of Bioengineering, University of Texas at Dallas, Texas, 75080, USA,*

7 ³*Department of Biomedical Engineering, University of Cincinnati, Ohio, 45220, USA,*

8 ⁴*Vascular Biology Program, Boston Children's Hospital, and Harvard Medical School, 02115, USA and*

9 ⁵*Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, 02115, USA*

10 ⁺Current address: *StataDX Inc., Boston, MA 02215, USA*

11

12 *Address all correspondence to: Donald E. Ingber, MD, PhD., Wyss Institute at Harvard University,
13 CLSB5, 3 Blackfan Circle, Boston MA 02115 (ph: 617-432-7044, fax: 617-432-7828; email:
14 don.ingber@wyss.harvard.edu

15

16 **Abstract**

17 **Simultaneous detection of multiple disease biomarkers in unprocessed whole blood is**
18 **considered the gold standard for accurate clinical diagnosis. Here, we report the development of a**
19 **4-plex electrochemical (EC) immunosensor with on-chip negative control capable of detecting a**
20 **range of biomarkers in small volumes (15 μ L) of complex biological fluids, including serum,**
21 **plasma, and whole blood. A framework for fabricating and optimizing multiplexed sandwich**
22 **immunoassays is presented that is enabled by use of EC sensor chips coated with an ultra-selective,**
23 **antifouling, nanocomposite coating. Cyclic voltammetry evaluation of sensor performance was**
24 **carried out by monitoring the local precipitation of an electroactive product generated by**
25 **horseradish peroxidase linked to a secondary antibody. EC immunosensors demonstrated high**
26 **sensitivity and specificity without background signal with a limit of detection in single-digit pg/mL**
27 **in multiple complex biological fluids. These multiplexed immunosensors enabled simultaneous**
28 **detect of four different biomarkers in plasma and whole blood with excellent sensitivity and**

1 **selectivity. This rapid and cost-effective biosensor platform can be further adapted for use with**
2 **different high affinity probes for any biomarker, and thereby create for a new class of highly**
3 **sensitive and specific multiplexed diagnostics.**

4

5 **Key Words:** Electrochemical Biosensor, Fabrication, Surface Chemistry, Hematocrit, Multiplexing,

6

7 **1. Introduction**

8 The ongoing paradigm shift from reactive healthcare to preventive health care has increased
9 interest in patient-centric diagnostic devices that could be used in everyday life. Direct detection of
10 relevant disease biomarkers in whole blood could circumvent expensive and time-consuming sample
11 preparation procedures that are currently required in clinical laboratories so that diagnostic assays could be
12 performed in point-of-care (POC) settings, including physicians offices, pharmacies, and even at home.^[1]
13 Widely used detection techniques like optical detection cannot be used for whole blood detection because
14 of strong scattering, absorption, and considerable autofluorescence in these complex biological samples.^[2]
15 Complex biological fluids, such as whole blood, plasma, and serum are also difficult to analyze due to
16 high concentrations of sticky proteins and other molecules that can reduce signal detection and increase
17 background noise. While some of these negative effects can sometimes be partly reduced by sample
18 dilution, many biomarkers are present near the assay's detection limit, and the dilution of samples is not
19 always linear.^[3]

20 One potential way to overcome these diagnostic challenges is through the use of electrochemical
21 (EC) sensors that can provide rapid, accurate, and quantitative detection of disease biomarkers in complex
22 fluids.^[4] Because they generate an electrical signal as an output, they also can seamlessly integrate with
23 wireless data collection and transmission systems. But while significant basic research has been
24 conducted on developing multiplexed EC POC devices for disease diagnosis, very few products have
25 been translated to the clinical setting.^[5] There are various reasons for this, including biofouling of
26 electrodes by components with complex biological fluids (sweat, saliva, blood, plasma), the complexity
27 of building bioassays on the electrodes, challenges related to development of multiplexing capabilities,
28 sensitivity to changes in environmental cues, and the need to develop sophisticated readouts and
29 analytical tools for analysis of complex data generated with these types of devices.^[6]

30 We have recently developed an engineering solution to address these challenges and create a
31 clinically translatable EC platform for rapid detection and quantification of clinically relevant disease
32 biomarkers in small volumes of complex biological fluids, including whole human blood. Key to this

1 advance was the development of a novel antifouling electroconductive nanocomposite coating to combat
2 EC biosensors, which enabled engineering of an EC sensor platform that provides effective and accurate
3 detection of several biomarkers that may be used for diagnosis of various diseases with clinical
4 significance.^[5, 7] The coating method involves brief (1 minute), localized, heat-induced coating of EC
5 sensors with a nanocomposite composed of denatured bovine serum albumin cross-linked with
6 pentaamine functionalized graphene oxide cross-linked with glutaraldehyde (BSA/prGOx/GA).^[8]

7 Multiplexing is a critical requirement for POC devices because disease and pathophysiology often
8 involves interplay among many complex biological processes, and hence accurate diagnosis requires
9 detection of several molecules rather than a single biomarker entity.^[4c, 9] Establishment of a multiplexed
10 detection platform therefore makes it possible to stratify and monitor complex multifactorial diseases with
11 high confidence in conjunction with relevant validated biomarkers.^[10] In addition, multiplexing minimizes
12 assay costs, time, and sample volume while concurrently enabling efficient monitoring and prediction of
13 disease progression and outcome.^[11] To develop this type of multiplexed platform, it is imperative to
14 immobilize optimized concentrations of high affinity bioreceptor molecules for the target of interest on
15 the electrode surface, which in combination with a specific detection antibody provides a high level of
16 signal sensitivity. The coating density of bioreceptors on the electrode surface is critical in achieving the
17 optimal surface-to-volume ratio necessary for the efficient capture and detection of the biomarker in the
18 test sample.^[12]


19 Here, we describe methods and tools that can be used to biofunctionalize nanocomposite coated
20 multi-electrode sensor chips and to assess sensor functionality to detect multiple analytes in the presence
21 of complex biological fluids. A sandwich enzyme-linked immunosorbent assay (ELISA) is employed for
22 signal detection that uses secondary antibodies linked to horseradish peroxidase (HRP) enzyme, which
23 generate an electroactive, insoluble, 3,3',5,5'-Tetramethylbenzidine (TMB) product that precipitates locally
24 at the molecular binding site above the electrode surface, and thereby enables a multiplexing capability.
25 Different assay parameters were optimized to create an immunoassay with optimum probe density and
26 TMB precipitation to develop a multiplexed assay with required sensitivity and specificity without
27 electrochemical background signal. Using this approach, an immunoassay with single-digit pg/mL
28 sensitivity was developed that was not influenced by clinically relevant hematocrit levels in whole blood,
29 which can potentially be translated into development of diagnostics for POC settings. We describe how
30 we used framework for sensor assay development to create optimized EC sensors that enable multiplexed
31 detection of a range of protein biomarkers for multiple clinically relevant conditions and disease,
32 including sepsis, active pulmonary tuberculosis (TB), myocardial infarction (MI), traumatic brain injury
33 (TBI), and multiple sclerosis (MS).

1 2. Results

2 2.1 Fabrication of electrochemical biosensors

3 The methods used for fabrication of our EC sensors are critical for their high functionality. Clean
4 gold sensor electrodes were first treated with plasma cleaner for 8 min (**Figure S1**, Supporting
5 Information) and modified with bioinspired nanocomposite coating composed of glutaraldehyde (GA)
6 cross-linked with denatured bovine serum albumin (BSA) intercalated with pentaamine modified reduced
7 graphene nanoparticles (prGOx) via rapid coating method as described previously^[8a] prior to
8 immobilizing antibodies (**Figure 1**). Importantly, we also found that this antifouling coating application
9 method can also be applied to other relevant electrode materials, such as a gold electroplated printed
10 circuit board (PCB) on polyethylene terephthalate (PET) substrate from Linxens and a 3D graphene foam-
11 based sensing electrode (Gii-Sens, from Integrated Graphene). Cyclic voltammetry (CV) analysis of the
12 coated Linxens sensors confirmed that they maintain similar currents as the bare electrode (**Figure S2**,
13 Supporting Information). On the other hand, a slight decrease in the peak current was observed after
14 coating the Gii-sens electrodes, which could be attributed to the porous structure of graphene foam, which
15 was filled after applying the coating (**Figure S3a**, Supporting Information).

16 The coating on these sensors was then activated with 1-ethyl-3-[3-dimethylami- npropyl]-
17 carbodiimide hydrochloride/ N-hydroxysuccinimide (EDC/NHS) and incubated with bioreceptor
18 molecules (i.e., capture antibodies), resulting in the formation of covalent links between free carboxylate
19 groups of the coating and primary amines of the antibody; unreacted carboxylate groups were
20 subsequently quenched with ethanolamine (**Figure 1b**). Although there was a slight decrease in the
21 current with coated Gii-sens electrodes, functionalization of the coated electrode directly with HRP
22 enzyme (as a positive control) only showed a high signal when its TMB substrate was added with no
23 signal in negative control (**Figure S3b**, Supporting Information). Thus, these findings indicate that the
24 antifouling nanocomposite coating can be applied to various kinds of sensors and support selective
25 binding of desired capture molecules on top of the electrode surface.



1
2 **Figure 1:** 3D schematic of sandwich immunoassay on biosensor coated with antifouling nanocomposite.
3 a) Electrochemical sensor with gold electrodes coated with the antifouling nanocomposite at 85 °C for
4 45s. b) Immobilization of capture antibody followed by quenching and blocking with bovine serum
5 albumin. c) Incubation of sample mixed with biotinylated detection antibodies. d) Addition of streptavidin
6 poly-HRP. e) Addition of precipitating TMB and subsequent precipitation over the gold electrode in EC
7 biosensor. f) Cyclic voltammogram for the measurement of NF-L in whole blood using biosensor with
8 anti-fouling coating.
9


10 Coated immunosensors with immobilized capture antibodies were then exposed to samples
11 containing the antigen and a secondary biotinylated detection antibody. Upon incubation, the specific
12 antigen is sandwiched between the capture and biotinylated detection antibodies (**Figure 1c**). Next, the
13 sensors are washed and exposed to streptavidin poly-horseradish peroxidase (spHRP), which binds to the
14 biotinylated detection antibody (**Figure 1d**). Finally, the TMB substrate for the HRP enzyme is added,
15 which results in production of an insoluble electroconductive product that locally precipitates at the
16 reaction site and is electrochemically read using cyclic voltammetry (**Figure 1e**). Typical CVs are
17 obtained with the immunosensor, where the peak height is directly proportional to the amount of target
18 detected (**Figure 1f**).
19

20 2.2 Electrochemical immunoassay development

21 The nanocomposite-coated EC sensors can be used to develop both two-step (incubation of
22 sample followed by washing and addition of detection antibody) and single-step (incubation with

1 pre-mixed sample and detection antibody) assays; however, their effectiveness requires
2 optimization of critical reagents and processes that are used to define assay performance. Using
3 the nanocomposite coating, we found that the highest sensitivity and specificity were achieved
4 by optimizing the concentration of capture and detection antibody, spHRP, as well as the TMB
5 incubation time. Initially, a two-step assay was evaluated using the MI biomarkers, cardiac
6 troponin I (cTnI) and N-terminal (NT)-pro hormone BNP (NT-proBNP), as targets. These
7 biomarkers show variable levels in circulation according to the clinical condition and timing of
8 measurement and thus require a rapid and sensitive POC device for clinical use.^[13] Plasma
9 samples were added to the EC sensor followed by an optimized concentration of 1 $\mu\text{g}/\text{mL}$
10 detection antibody to achieve a sensitivity of 24 and 3 pg/mL for cTnI and NT-proBNP,
11 respectively, with assay times of 1 h and 21 min (**Figure S4**, Supporting Information). The EC
12 sensor also was not able to achieve the clinical threshold for cTnI, which is 16 pg/mL in
13 female.^[13b]

14
15 Assay development was then carried out to develop a rapid biosensor with decreased assay time
16 while maintaining high sensitivity and specificity for single-step detection of the different
17 biomarkers. Surface coverage plays a critical role in defining the performance of the EC sensor
18 and can be optimized to reduce steric hindrance for efficient binding. Different concentrations of
19 anti-cTnI capture antibody (50 $\mu\text{g}/\text{mL}$ -1000 $\mu\text{g}/\text{mL}$) were evaluated to detect high, low and zero
20 concentrations of the analyte (10, 0.1, and 0 ng/mL , respectively). The electrical signal generated
21 with the 10 ng/mL analyte increased as the concentration of the capture antibody was raised from
22 50 to 500 $\mu\text{g}/\text{mL}$ as expected but it decreased when the antibody concentration was further raised
23 from 500 to 1000 $\mu\text{g}/\text{mL}$, which may be due to surface crowding (**Figure 2a**).^[14] 500 $\mu\text{g}/\text{mL}$ of
24 capture antibody also resulted in the highest signal-to-noise ratio, and a significant difference
25 between lowest concentration and blank. This 500 $\mu\text{g}/\text{mL}$ capture antibody concentration was
26 then used to optimize the detection antibody concentration in the range of 1-8 $\mu\text{g}/\text{mL}$ with high,
27 low, and blank analyte.



1
 2 **Figure 2:** Optimization of assay condition for detection of cTnI in EC biosensor. a) Optimization of cTnI
 3 capture antibody. Bar graph shows the mean current density for different concentration of capture
 4 antibody (50, 100, 500, and 1000 µg/mL) to perform assay of cTnI at 3 different concentrations (10, 0.1,
 5 and 0 ng/mL). b) Optimization of cTnI detection antibody. Bar graph shows the mean current density for
 6 different concentration of detection antibody (1, 2, 3, 5, and 8 µg/mL) to perform assay of cTnI at 3
 7 different concentrations (10, 0.1, and 0 ng/mL). c) Optimization of Streptavidin-poly-HRP (spHRP). Bar
 8 graph shows the mean current density for different concentration of spHRP (1, 2, 3, 5, and 8 µg/mL) to
 9 perform assay of cTnI at 3 different concentrations (10, 0.1, and 0 ng/mL). d) Optimization of TMB
 10 incubation time. Bar graph shows the mean current density for different incubation time for TMB (1 and
 11 2 min) to perform assay of cTnI at different concentrations (10, 1, 0.5, 0.1, 0.05, 0.01, and 0 ng/mL).
 12 Error bars represent the s.d. of the mean; n=3. Significant difference was determined by unpaired two-
 13 tailed t-test (ns $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$).

14
 15 Using this optimized biosensor, we found that the signal for 10 ng/mL analyte increased when
 16 the concentration of anti-cTnI detection antibody was raised from 1 to 2 µg/mL, the signal then
 17 plateaued from when the concentration was further increased from 2 to 5 µg/mL, and it finally
 18 declined from 5 to 8 µg/mL (**Figure 2b**), which could be due to over precipitation of TMB

1 making the surface less conductive. A signal for lower concentration (0.1 ng/mL) of analyte was
2 seen only for detection antibody concentrations of 5 µg/mL and above, while 8 µg/mL of
3 detection antibody resulted in non-specific binding similar to that observed for the blank.

4
5 We then used 5 µg/mL of detection antibody that had the highest signal-to-noise ratio to further
6 optimize spHRP. Using 10 ng/mL of analyte, we found the signal generated to be consistent
7 when we added 1 to 5 µg/mL spHRP, but with higher concentrations, there was over
8 precipitation of substrate leading to a decrease in signal (**Figure 2c**). Lowest concentration (0.1
9 ng/mL), started showing signal when concentration of spHRP was 3 µg/mL or higher with no
10 significant difference between lowest concentration and blank at 3 µg/mL of spHRP. At 5 µg/mL
11 of spHRP, there was a significant difference between 0.1 ng/ml and blank. However, a high non-
12 specific signal was observed at 8 µg/mL spHRP. Thus, we viewed 5 µg/mL spHRP to be the
13 optimal concentration for use in these studies.

14
15 Finally, all the optimized conditions were used to evaluate the TMB precipitation time.
16 Calibration curves were run from 0.01 to 10 ng/mL with a TMB precipitation time of 1 versus 2
17 min. With the 1 min precipitation time, no signal was observed for lower TMB concentrations
18 (0.05 and 0.01 ng/mL); however, signals were observed over the whole calibration range with
19 the 2 min precipitation (**Figure 2d**). Longer precipitation times led to a non-specific signal, so
20 the 2 min TMB precipitation time was considered optimum for the assay.

21
22 The coating time of the sensor with antifouling nanocomposite was also assessed by performing
23 the EC sandwich assay for detection of 4 different concentrations (1, 0.1, 0.05, and 0 ng/mL) of
24 cardiac troponin complex (cTnITC). We found that there was no significant difference at higher
25 concentrations, but the 45 sec coating time gave the highest signal-to-noise ratio at lower analyte
26 concentration (0.05 ng/mL) (**Figure S5a**; Supporting Information), and thus coating time of 45
27 sec was used for all subsequent studies. Interestingly, we found that this 45 sec rapid coating
28 procedure resulted in production of bioassays that were as sensitive as those previously created
29 using a 24 h coating^[8b], as demonstrated by the absence of any significant difference in the signal
30 generated in the cTnITC assay at lower analyte concentrations (**Figure S5b**, Supporting
31 Information). In addition, the biosensors can be stored at room temperature for at least a week

1 after the completion of the assay^[8a] and still generate a similar signal. For example, when we ran
2 a full calibration curve (0.01 to 10 ng/mL cTnITC) there was no significant difference between
3 the signal read out immediately after sensor fabrication or after incubating in the dark for 24 h
4 (**Figure S5c**, Supporting Information).


5
6 As the ultimate aim was to perform a multiplexed assay with the same reagents, the spHRP
7 concentration and TMB precipitation time were kept constant, and only the detection antibody
8 concentration was optimized for the other biomarkers. Similar to optimization of the anti-cTnI
9 detection antibody, we found that 9 µg/mL of anti-BNP detection antibody and 6 µg/mL of anti-
10 NT-proBNP and anti-cTnITC complex detection antibodies gave the highest signal-to-noise
11 ratios (**Figure S6a-c**, Supporting Information). Furthermore, similar to the biomarkers for MI,
12 we also optimized capture and detection antibody concentration for previous described
13 biomarkers for active pulmonary TB.^[15] We found that 1 mg/mL was the optimal capture
14 antibody concentration for interleukin-6 (IL-6), IL-8, IL-18, and vascular endothelial growth
15 factor (VEGF) using an optimal concentration of detection antibody of 2 µg/mL (**Figure S7,8**,
16 Supporting Information).

18 2.2 EC biosensor analytical performance

19 To explore the potential value of this approach for clinical diagnostics, we leveraged these
20 biomarkers to construct a prototype POC affinity-based ELISA on miniaturized electrodes,
21 which could be used to develop a low-cost, rapid, ultra-low volume, and easily accessible blood-
22 based triage test for TB. We performed sandwich ELISA on the EC biosensor containing the
23 immobilized capture antibodies for the TB biomarkers described above and carried out
24 calibration curves covering their clinical ranges (**Figure 3**). We obtained a limit of detection
25 (LOD) of 1000, 3, 9, 5, and 17 pg/mL for Ag85-B, IL-6, IL-8, IL-18, and VEGF, respectively.
26 Importantly, the LODs for all of the TB biomarkers were better than the clinical cut-off values
27 (**Table 1**, Supporting Information).^[15-16]

28
29 To explore the generality of this approach, we carried out a similar EC sandwich assay using
30 specific capture antibodies for procalcitonin (PCT), a 116-amino acid peptide precursor for
31 calcitonin which has a strong association with hepatitis C virus (HCV), sepsis, and other

1 bacterial infections. We obtained LOD of 4 pg/mL, which is also more sensitive than the clinical
2 cut-off value (**Table 1**, Supporting Information).^[10, 17] In addition, we performed a neurofilament
3 light polypeptide (NF-L) assay using unprocessed whole blood on the Linxens sensor. NF-L is
4 considered a promising biomarker for MS that has been shown to reflect disease activity in the
5 clinical follow-up of the MS patients.^[18] With the Linxens sensor, a LOD of 0.3 pg/mL was
6 obtained for NF-L using whole blood, which can be attributed to the highly efficient antifouling
7 capability of our nanocomposite coating (**Figure S9**, Supporting Information).



8
9 **Figure 3:** Calibration curves for different biomarkers using antifouling nanocomposite coated EC
10 Biosensors. The left y-axis shows the current intensity for different concentrations of biomarkers run on

1 *EC biosensors using unprocessed human plasma. Different biomarkers tested include a) IL-6, b) IL-8, c)*
2 *IL-8, d) VEGF, e) Ag85B, and f) PCT. Error bars represent the s.d. of the mean; n = 3. Analysis was*
3 *done using 4-Parameter Logistic (4PL) curve fitting.*
4


5 2.3 Cross-reactivity of Antibody pair and Antigen

6 Cross-reactivity can be a significant issue in diagnostic immunoassays as it can result in over-or
7 underestimation of sample analyte concentration.^[19] Thus, we performed a detailed cross-
8 reactivity study for different pairs of MI and TBI antibodies and antigens, including NT-proBNP,
9 in conventional plastic ELISA plates (**Figure 4a**). Using an anti-NT-proBNP capture antibody
10 with 10 ng/mL of the NT-proBNP analyte, we found that addition of multiple different
11 secondary detection antibodies, including those directed against cTnI, BNP, S100, and glial
12 fibrillary acidic protein (GFAP), failed to generate any detectable signal compared to the blank,
13 confirming that there is no non-specific binding of detection antibodies or cross-reactivity in this
14 assay.

15
16 We also explored whether the NT-proBNP analyte binds non-specifically to other capture
17 antibodies (anti-cTnI, anti-BNP, anti-S100, and anti-GFAP) by coating ELISA plates with
18 different capture antibodies followed by the addition of 10 ng/mL NT-proBNP and anti-NT-
19 proBNP detection antibody. A minimum signal similar to blank was observed in each case
20 (**Figure 4a**), again showing no cross-reactivity. Likewise, cross-reactivity of antibody pairs and
21 antigens were also performed for BNP, GFAP, and S100 with all other capture and detection
22 antibodies (**Figure 4b,c,d**). Concentration-based signals were observed only for specific
23 antibody pairs, and no signal was observed using non-specific antibodies or target analytes; thus,
24 these antibody pairs (NT-proBNP, BNP, GFAP, and s100) can be used for multiplexed detection
25 in single assay.

26
27 For Troponin I, two antibody pairs (anti-cTnI and anti-cTnI-TC) were tested for cross-reactivity
28 with other antibody pairs (BNP, NT-proBNP, GFAP, and s100) along with specific analytes,
29 cTnI and cTnITC complex. We were able to demonstrate specific detection of cTnITC with an
30 anti-cTnI antibody pair, which produced a lower specific signal and higher non-specific binding
31 with BNP and a NT-proBNP capture antibody(**Figure S10a**; Supporting Information). We also
32 obtained a concentration-dependent signal for cTnI with using anti-cTnI antibody pair, but

1 observed very high non-specific binding of cTnI to BNP and NT-proBNP capture antibodies
 2 (**Figure S10b**; Supporting Information). Similar high specific signals were obtained for cTnITC
 3 using anti-cTnI-TC antibody pair, while there was almost no signal with the non-specific
 4 antibody pair (**Figure S10c**; Supporting Information). There was also very low specific binding
 5 of the anti-cTnI-TC antibody pair for cTnI (**Figure S10d**; Supporting Information). Thus, we can
 6 use the anti-cTnI-TC antibody pair (**Figure S10c**) with high specific signal for cTnITC and
 7 minimum cross-reactivity to other antibody pairs to create multiplexed assays for detection of MI
 8 and TBI biomarkers. In addition, we found that the assays for the cytokines IL-6 and IL-18 also
 9 only specifically react with their own capture and detection antibody pair and do not cross-react
 10 with antibody pairs against other interleukin types (IL-6, IL-8, and IL-18)(**Figure S11**;
 11 Supporting Information).
 12



13
 14 **Figure 4:** Specificity and cross-reactivity test for different biomarkers of Myocardial Infarction (MI) and
 15 Traumatic Brain Injury (TBI) done in 96 well plate. a) Specificity and cross-reactivity of NT-proBNP
 16 antigen against different non-specific capture and detection antibodies (anti-cTnITC, anti-BNP, anti-


1 *GFAP, and anti-S-100b) along with specific detection with anti-NT-proBNP capture and detection*
2 *antibody at different concentrations of NT-proBNP. b) Specificity and cross-reactivity of BNP antigen*
3 *against different non-specific capture and detection antibodies along with specific detection with anti-*
4 *BNP capture and detection antibody at different concentrations of BNP. c) Specificity and cross-reactivity*
5 *of GFAP antigen against different non-specific capture and detection antibodies along with specific*
6 *detection with GFAP capture and detection antibody at different concentrations of GFAP. d) Specificity*
7 *and cross-reactivity of S-100b antigen against different non-specific capture and detection antibodies*
8 *along with specific detection with S-100b capture and detection antibody at different concentrations of*
9 *GFAP.*

10

11 2.4 Multiplexed Detection using Plasma and Whole Blood

12 The high sensitivity and selectivity of the antifouling nanocomposite combined with the use of
13 antibody pairs and corresponding target analytes that are free of any cross-reactivity made it
14 possible to create a highly multiplexed EC sensor for simultaneous detection of multiple
15 biomarkers both in plasma and whole blood. Different working electrodes in each EC sensor
16 were individually functionalized with one of four different capture antibodies directed against
17 cTnITC, S100, NT-proBNP, or anti-GFAP. Initially, we spiked plasma samples with different
18 concentrations of cTnITC (0.01-10 ng/mL) followed by all four detection antibodies and
19 observed a concentration-based signal only for cTnITC (**Figure 5a**), while minimal or no signals
20 were observed for the other biomarkers (S100, NT-proBNP, and GFAP) or in unspiked (blank)
21 plasma samples. We then spiked plasma samples with increasing concentrations of cTnITC
22 (0.01-10 ng/mL) and decreasing concentrations of GFAP (10-0.01 ng/mL) and observed specific
23 signal only for cTnITC and GFAP while no signal was observed for S100 and NT-proBNP along
24 with blank samples (**Figure 5b**). We then carried out similar multiplexed EC sensor assays in
25 human whole blood samples without any pre-treatment. In these studies, we were able to
26 specifically detect cTnITC and GFAP (**Figure 5c**) as well as S100 and GFAP (**Figure 5d**), and
27 develop calibration curves for each ligand simultaneously in multiplexed setting without
28 observing any cross-reactivity with the capture or detection antibodies even in unprocessed
29 whole blood.

30




1
 2 **Figure 5:** Specificity and Multiplexed detection for different biomarkers of MI and TBI using antifouling
 3 nanocomposite coated EC Biosensors. a) Calibration curve for multiplex detection of cTnITC using
 4 plasma sample on the EC Biosensor with four different capture antibodies on each electrode (anti-
 5 cTnITC, anti-S-100b, anti-GFAP, and anti-NT-proBNP). b) Calibration curve for multiplex detection of
 6 increasing concentration of cTnITC (left y-axis) and decreasing concentration of GFAP (right y-axis)
 7 using plasma sample (c) and whole blood (d) on the EC Biosensor with four different capture antibodies
 8 on each electrode. e) Calibration curve for multiplex detection of increasing concentration of s100 (left y-
 9 axis) and decreasing concentration of GFAP (right y-axis) using whole blood on the EC Biosensor with
 10 four different capture antibodies on each electrode. Error bars represent the s.d. of the mean; $n = 3$.
 11

12
 13 **2.5 Detection of biomarkers in different complex biological fluids**

14 For accurate disease diagnosis, a wide range of bodily fluids is employed in clinical settings,
 15 such as blood, serum, saliva, sputum, and sweat. However, the inherent biological and
 16 physiochemical properties of these complex fluids often hinders clinical diagnosis. The most

1 common problem is that molecules present within these fluids can interact with the analyte or
2 with the sensor surface, which leads to the reduction of the signal.^[20] The sensitivity of EC
3 sensors also can be reduced due to limited access of redox molecules or analytes to the sensor
4 surface in these samples that can be highly viscous and rich in cells as well as molecules.
5 Furthermore, most clinical biomarkers are present at very low concentrations (fM to pM range) in
6 these samples, and they can often cross-react with the large molecules, such as albumin and
7 immunoglobulins, which are present at much higher concentration (μM to mM range).^[21]
8 Biological samples are also unstable, and often environmental triggers have an impact in
9 antigen–antibody interaction, non-specific binding, and degradation of sample.^[21] Thus, the
10 detection of multiple biomarkers in clinical samples can provide different challenges due to the
11 complexities of the matrix.^[3] Given these observations, as the LOD is one of the critical
12 parameters in clinical bioassay, it must be measured in the complex fluid sample intended for use
13 using the complete sample preparation sequence required to carry out the assay.^[20-22]

14
15 We have tackled these issues by developing a highly efficient antifouling coating, carrying out
16 rigorous screening of antibodies, and optimizing assay development. To validate the
17 nanocomposite's antifouling effect and show that our EC biosensor can perform the assay in
18 different complex biological fluids, we compared the efficiency of a single-step sandwich assay
19 for GFAP in buffer, plasma, and whole blood (**Figure 6a**). As expected, we observed a similar
20 calibration curve in the range of 0.01 to 10 ng/mL in all three samples (LOD of GFAP in buffer,
21 plasma, and whole blood was 16, 7, and 2 pg/mL, respectively). The fact that the EC biosensor
22 with antifouling coating works similarly in unprocessed whole blood as well as plasma was also
23 demonstrated by showing that the calibration curve for NF-L in whole blood and plasma closely
24 overlap each other, with LODs of 10 and 3 pg/mL, respectively (**Figure 6b**).



1
2
3
4
5
6
7
8
9

Figure 6: Matrix effect for detection of different biomarkers on EC Biosensors. a) Calibration curve of GFAP using buffer (black dot), plasma (orange), and whole blood (purple) on EC Biosensor. b) Calibration curve of NF-L using plasma (black dot) and whole blood (blue) on EC Biosensor. c) Detection of different concentration of NF-L (1, 0.05, and 0 ng/mL) at different % of hematocrit (20%-70%). Line graph shows the mean current density for the assay of NF-L using plasma sample on EC biosensor. Error bars represent the s.d. of the mean; n = 3.

10 2.6 Effect of hematocrit levels

11 Hematocrit levels (erythrocyte concentrations) in blood fluctuate between individuals and
12 various disease states, and they can impact the accuracy of biomarker detection in whole blood
13 samples.^[23] We therefore measured the effect of different hematocrit levels (20%, 30%, 45%,
14 60%, and 70%) on the performance of the EC assay using a plasma sample as a control. When
15 we spiked these samples with two different concentrations of NF-L (0, 0.1, and 1 ng/mL) and

1 blank, there were no significant difference in the signals observed between samples with
2 different hematocrits or in the plasma sample (**Figure 6c**).

3

4 **3. Discussion**

5 In this study, we described development methods and optimization strategies for creation
6 of multiplexed EC sensors that can be used to detect clinically relevant biomarkers in complex
7 biological fluids, such as unprocessed whole blood and plasma, with high sensitivity and
8 specificity as well as minimal cross reactivity. The optimization of individual components in
9 sandwich immunoassays combined with the high efficiency antifouling coating enabled highly
10 sensitive detection with near-zero cross-reaction for selective biomarkers for MI, TBI, MS, and
11 TB when present in the clinically relevant range within plasma and blood samples. The ability of
12 these sensors to simultaneously detect multiple different biomarkers should allow for more
13 accurate detection and evaluation of diseases with a limited quantity of clinical samples, in
14 addition to offering the possibility of early diagnosis at POC.

15 We achieved multiplexing of four different biomarkers in the same sensor by antibody
16 screening, assay parameter optimization, and carrying out cross-reactivity studies. Potential
17 cross-reactivity was tested by replacing the actual antigen and antibodies (capture and detection)
18 with similar size proteins and non-specific antibodies. We consistently observed specific signals
19 for the real analytes with minimum readout when using non-specific molecules, which allowed
20 us to delineate the selectivity and also demonstrate superiority in terms of the accuracy of
21 detection. For instance, using NT-proBNP as cardiovascular disease protein biomarker, cross-
22 reactivity with non-specific protein biomarkers (BNP, cTnI, S100, and GFAP) was assessed
23 using similar sized antibodies and complex protein structures. When the capture antibodies
24 targeting the analytes were replaced with antibodies against other targets, the output signals were
25 consistently low or zero. In addition, the use of locally precipitating TMB allowed us to build
26 versatile multiplexed biosensors in close juxtaposition, each using a different antigen-antibody
27 pair, which do not cross-react.

28 EC sensors are not used often for clinical diagnosis or POC application largely because
29 they are prone to electrode fouling when used with complex biological fluids. By integrating an
30 antifouling nanocomposite coating, we were able to detect multiple disease biomarkers in

1 complex samples, such as human whole blood and plasma, and still obtain clinically relevant
2 LODs. Our studies on detection of the neurological disease biomarkers, GFAP and NF-L, also
3 demonstrated that hematocrit levels in blood had no significant effect on our EC biosensor with
4 antifouling coating. We expect that other biomarkers will show similar behaviors, but a detailed
5 study should be carried out with each biomarker explored in the future. Moreover, the same
6 antifouling coating worked equally well when integrating different kinds of EC sensors,
7 including screen printed electrodes and transducer-like materials. Thus, this antifouling coating
8 is a key feature of our EC sensors that provides a significant advantage that is highly relevant for
9 clinical diagnostics as well as POC applications.

10 Finally, as a proof-of-concept, we leveraged our multiplexed EC sensor to develop a TB
11 diagnostic. Nearly 10 million people develop TB every year and this results in approximately 1.5
12 million deaths worldwide each year even though it is entirely curable with early diagnosis and an
13 effective treatment plan.^[24] Current TB diagnostic tests are either difficult to access as they are
14 only available in hospital settings or they have low accuracy, reliability, yield delayed results,
15 and require expertise and specialized facilities. In addition, sputum sample collection from
16 suspected TB patients is cumbersome, exacerbating the difficulty in making a timely diagnosis.
17 An accurate POC device that could diagnose TB early and guide the use of medical treatment
18 would significantly improve the management of this disease in endemic areas, decreasing
19 morbidity and slowing disease transmission.^[25] A combination of TB disease-specific biomarker
20 Antigen (Ag)85B (Ag85-B) and host response cytokines IL-6, IL-8, IL-18, and VEGF were
21 previously combined to configure a blood-based triage test for active pulmonary TB based on
22 analysis of an extensive cohort study.^[15] Importantly, the performance of this biomarker panel
23 was validated by an independent blinded set of samples, and it meets the World Health
24 Organization's (WHO) minimal target product profile (TPP) for a blood-based TB triage test.
25 Thus, we believe that this new approach for fabricating multiplexed EC sensors can be used to
26 develop POC diagnostics that could have near-term impact on healthcare world-wide.

27 In summary, in this study, we have addressed four significant challenges including, i)
28 prevention of biofouling from the complex biological samples like blood, ii) choosing a coherent
29 group of biomarkers that is highly specific to a disease condition, iii) developing sensitive assay
30 without any cross-reaction, and iv) integrating the technology into a multiplexed EC sensor.

1 Combined, this approach enable rapid and cost-effective development of multiplexed biosensors
2 that provide highly sensitive and specific detection of various clinically relevant biomarkers for
3 complex diseases, as we demonstrated for TB, MI, and TBI. They also can be adapted to detect
4 any desired analyte if appropriate specific capture and detection molecules (e.g., antibodies,
5 aptamers, etc.) are available. Thus, these multiplexed EC sensor arrays could provide a new
6 approach to disease diagnosis as well as environmental monitoring in POC settings.

7

8 **4. Methods**

9 **4.1 Fabrication of Electrochemical (EC) sensor**

10 The EC sensor with gold electrodes which was purchased from Telic Company was custom
11 fabricated using a standard photolithography process. The chips were cleaned by sonicating in acetone
12 followed by isopropyl alcohol and cleaned with plasma cleaner for 8 min as described previously.^[8b]
13 Antifouling coating solution consisting of prGOx and BSA crosslinked with GA was drop-casted over the
14 chips at 85 °C for 45s.^[8a] The chips were then washed by dipping in PBS immediately at 400 rpm for 10
15 min.

16

17 **4.2 Conjugation of Capture Antibodies**

18 After drying the coated chips with a slide spinner (Millipore Sigma, no. 674 664), 400 mM EDC
19 (Thermo Fisher Scientific, no. 22 980) and 200 mM NHS (Sigma-Aldrich, no. 130 672) were dissolved in
20 0.05 M MES (2-(N-morpholino)ethanesulfonic acid) Buffer (pH 6.2) and deposited over the chips for 30
21 min at room temperature in dark. The chips were then quickly rinsed with Milli Q water and dried with
22 compressed air followed by spotting of optimized concentration of capture antibody on top of three
23 working electrodes and BSA (5 mg/mL) over the 4th electrode as a negative control using Xtend capillary
24 microarray Pin (LabNEXT, no. 007-350). The chips spotted with capture antibody and BSA were stored
25 overnight at 4 °C in a humidity chamber followed by washing with PBS. The chips were then exposed to
26 1 M ethanolamine (Sigma-Aldrich, USA, no. E9508) in PBS to quench the unreacted glutaraldehyde
27 groups for 30 min and blocked with 10 µL of 2.5% BSA in PBS for 1 h.

28

29 **4.3 Detection of Biomarkers in EC Sensor**

30 Detection of different biomarkers on the EC biosensor was performed using the optimized
31 conditions. Three working electrodes were spotted with respective capture antibodies diluted in PBS
32 [anti-BNP (HyTest, no. 50E1cc), anti-NT-proBNP (Medix Biochemica, no. 100 521), anti-cTnI (Abcam,
33 no. ab243982), anti-cTnI-TC (Advanced ImmunoChemical, no. 2-TIC-rc) anti-GFAP (HyTest, no.

1 GFAP83cc), anti-S100b (HyTest, no. 8B10cc)], anti NF-L (Uman Diagnostics, no. 27016), anti-IL-6
2 (Abcam, ab246838), anti-IL-8 (Abcam, ab215402), anti-IL-18 (Abcam, ab218185), anti-VEGF (R&D
3 system DY493-05), and anti-Ag85-B (Abcam, ab36731). Antigens were then spiked into the plasma
4 samples at different concentrations ranging from 1 pg/mL to 10,000 pg/mL and mixed with the optimized
5 concentration of biotin conjugated detection antibody in the ratio of 9:1. Different antigens used includes
6 [BNP-32 (Bachem, no. 4 095 916), NT-proBNP (Medix Biochemica, no. 610 090), cTnI (Medix
7 Biochemica, no. 610 102), cTnI-TC complex (HyTest, no. 8T62), GFAP (HyTest, no. 8G45), S100b
8 (HyTest, no. 8S9h), NF-L (Encor, no. PROT-r-NF-L), IL-6, IL-8, IL-18, VEGF, and Ag85-B,
9 respectively. 15 μ L of the sample detection antibody mixture was then added to the EC biosensor and
10 incubated with agitation at 400 rpm for 30 min (single-step assay). For 2 step assay, 15 μ L of the sample
11 antigen was incubated for 1 h followed by washing and the addition of 10 μ L of detection antibody for 15
12 min. Conjugation of biotin to detection antibody was done using Biotin Conjugation Kit (Fast, Type A)–
13 Lightning-Link (Abcam, USA, no. ab201795) using manufacturer’s protocol except for anti-NF-L
14 detection antibody which was already linked with biotin when purchased. Detection antibodies used for
15 the assay include anti-BNP (HyTest, no. 24C5cc), anti-NT-proBNP (Medix Biochemica, no. 100 712),
16 anti-cTnI (Abcam, no. ab243982), anticTnI-TC (Advanced ImmunoChemical, USA no. 2-TC), anti-
17 GFAP (HyTest, no. GFAP81cc), anti-S-100b (HyTest, no. 6G1cc), anti NF-L (Uman Diagnostics, no.
18 27018), anti-IL-6, anti-IL-8, anti-IL-18, anti-VEGF, and anti-Ag85-B, respectively. After 30 min
19 incubation, the EC biosensors were washed with PBST (PBS with 0.05% Tween 20 (Sigma-Aldrich, no.
20 P9416)). 2-5 μ g/mL of spHRP (Thermo Fisher Scientific, no. N200) diluted in 0.1% BSA in PBST was
21 then added to each EC biosensor for 5 min followed by washing and addition of precipitating TMB,
22 Sigma-Aldrich, USA, no. T9455) membrane substrate for 2 min. The EC biosensors were finally washed
23 with PBST before taking the electrochemical measurements in PBST using a potentiostat by a CV with a
24 scan rate of 1 V/s between -0.5 and 0.5 V versus on-chip integrated gold quasi reference electrode.
25 Linxens sensor was cleaned by dipping in 50 mg/mL sodium carbonate for 10s followed by rinsing in
26 water and dipping in 920 mM sulfuric acid for another 10s before final rinse with water. Gii-sens
27 electrode were directly used without cleaning. Linxens and Gii-sens electrode were characterized by
28 measuring CV in PBS containing 5 mM $[\text{Fe}(\text{CN})_6]^{3-/4-}$ at 200 mV/s between -0.5 to 0.5 V. All samples
29 were collected under the approval of the Institutional Review Board for Harvard Human Research
30 Protection Program (IRB21-0024).

31

32 **4.4 Cross-reactivity**

33 Specificity of Antigen and Antibody was performed in Nunc™ MaxiSorp™ ELISA plates
34 (BioLegend, no. 423501). For each biomarker four different concentrations were run with specific

1 antibody pairs to observe the signal for specific binding. To see if there is any non-specific binding of
2 antigen to capture antibody of other biomarkers, all the non-specific capture antibodies were coated to the
3 plates followed by the addition of high concentration analyte (10 ng/mL) and negative control (0 ng/ml)
4 and detection antibody for the analyte. To test non-specific binding between the antigen and detection
5 antibody of other biomarkers, a specific capture antibody was coated to the plate and a high concentration
6 analyte (10 ng/mL) and negative control were added to the plate followed by all other non-specific
7 detection antibodies. All the assays were performed in buffer (1 % BSA in PBS). For instance, in case of
8 BNP specificity test, four concentrations of BNP (0, 0.1, 1, and 10 ng/mL) (black dots, **Figure 4b**) were
9 tested with specific antibody pair for BNP. For non-specific capture antibody-antigen binding test, four
10 different capture antibodies (anti-NT-pro BNP, anti-cTnI, anti-GFAP, and anti-S100) were coated at 1
11 $\mu\text{g/mL}$ followed by the addition of either 10 ng/mL or 0 ng/mL of BNP. After washing anti-BNP
12 detection antibody was added followed by Streptavidin-HRP and TMB (ThermoScientific, no. 34022).
13 Similarly, for the non-specific antigen-detection antibody binding test, BNP capture antibody followed by
14 0 or 10 ng/mL of BNP was added. After washing, non-specific biotinylated detection antibodies (anti-NT-
15 proBNP, anti-cTnI, anti-GFAP, and anti-S100) were added followed by Streptavidin-HRP and TMB.
16 Likewise, specificity test for other biomarkers including NT-proBNP, GFAP, and S100 was done in
17 similar way with specific and non-specific antigen-antibody pairs. Similarly, for cTnI and cTnITC
18 specificity test was performed with both Abcam antibody pair (specific to cTnI) and Advanced
19 ImmunoChemical antibody pair (specific to cTnITC). Likewise, cross-reactivity test was also performed
20 for different biomarkers of TB including Il-6, IL-8, and IL-18.

21

22 **4.5 Multiplexed detection of Biomarkers in EC Platform**

23 For the detection of cTnITC in multiplexed EC biosensor, four different capture antibodies (anti-
24 cTnITC, anti-S100, anti-NT-proBNP, and anti-GFAP) were spotted on four different electrodes of the
25 chip at 500 $\mu\text{g/mL}$. Increasing concentration of cTnITC (0, 0.01, 0.05, 0.1, 1, and 10 ng/mL) spiked in
26 plasma samples were mixed with optimum concentration of all four biotinylated detection antibodies and
27 added to the EC biosensor for 30 min. Chips were washed and spHRP was added for 5 min followed by
28 TMB for 2min before washing and reading the chips. In the next experiment for parallel detection of
29 cTnITC and GFAP, all capture antibodies were spotted as earlier. Increasing concentration of cTnITC and
30 decreasing concentration of GFAP (0.01 cTnITC + 10 GFAP; 0.05 cTnITC +1 GFAP; 0.1 cTnITC + 0.1
31 GFAP; 1 cTnITC + 0.05 GFAP; 10 cTnITC + 0.01 GFAP) spiked in plasma samples was mixed with all
32 four biotinylated detection antibody and incubated for 30 min. Likewise, simultaneous multiplexed
33 detection of cTnITC and GFAP was performed in unprocessed whole blood with increasing concentration
34 of cTnITC and decreasing concentration of GFAP (0.01 cTnITC + 10 GFAP; 0.05 cTnITC +1 GFAP; 0.1

1 cTnITC + 0.1 GFAP; 1 cTnITC + 0.05 GFAP; 10 cTnITC + 0.01 GFAP). Similarly, simultaneous
2 multiplexed detection of S100 and GFAP in the whole blood sample was also performed.

4 **4.6 Matrix and hematocrit effects**

5 The effect of different types of matrices on the performance of EC biosensor was evaluated by
6 running the calibration curve of GFAP using buffer (2.5 % BSA in PBS), plasma, and whole blood
7 sample with the optimized conditions. The antifouling effect of different matrix components was further
8 evaluated by running a calibration curve of NF-L in plasma vs unprocessed whole blood. To study the
9 hematocrit effect, whole blood samples collected in Sodium heparin tube was used to separate plasma
10 from RBCs. Briefly, Heparinized tubes were centrifuged for 10 minutes at 1,500 x g using a refrigerated
11 centrifuge. Following centrifugation, plasma was immediately transferred into a clean polypropylene tube
12 using a pipette and kept over ice. Blood samples with different nominal hematocrit values in the range of
13 20 to 70% were then prepared by mixing different ratios of plasma and RBCs followed by gentle mixing.
14 EC assay of NF-L was immediately performed after the preparation of plasma and whole blood with
15 different hematocrit levels.

17 **4.7 Statistical Analysis**

18 ELISA reading is reported as absorbance (a.u.) of the mean of replicates and error bars represent
19 the standard deviation (s.d.) of the mean; n = 2. For EC biosensor studies, peak heights were calculated
20 using Nova 1.11 software. For data analysis peak height (μA) was converted to current density ($\mu\text{A}/\text{mm}^2$)
21 for further analysis by dividing the peak height by the surface area of the working electrode (0.1576
22 mm^2). Error bars represent mean \pm s.d. for all EC biosensor studies (sample sizes and statistical tests used
23 are indicated in the Figure legends). All data were plotted, and statistical tests were performed using
24 GraphPad Prism 8, and 4-Parameter Logistic (4PL) curve fitting was done for calibration curve analysis.

26 **Supporting Information**

27 Supporting Information is available from the Wiley Online Library or from the author.
28 Supporting Information includes optimization of coating time, TMB stability, Linxens and Gii-sens
29 characterization, two-step calibration curves, optimization studies, cross-reactivity studies, and calibration
30 curve.

1 Acknowledgments

2 We would like to acknowledge Linxens and Integrated Graphene for providing the electrodes for
3 the study. This work was supported by the Wyss Institute for Biologically Inspired Engineering at
4 Harvard University. MR was supported from Internal funding from bioengineering at UTD

6 Author contributions

7 SS, MR, ND conceived the study under the guidance of RA, PJ, and DEI. MR under the guidance
8 of RA and PJ contributed to TB-related work. Experiments were performed and validated by SS, MR, and
9 ND. All authors contributed to discussion, manuscript preparation, and editing.

10

11 Conflict of Interests

12 This technology has been licensed to Antisoma Therapeutics Inc. for infectious disease and
13 cancer diagnostics and to StataDX Inc. for neurological and kidney disease diagnostics; P.J. and D.E.I.
14 hold equity in StataDx and D.E.I. is a board member; S.S.T., N.D., P.J., and D.E.I are also listed as
15 inventors on patents describing this technology. RA is listed as inventor on a patent for the TB
16 biomarkers (IL-6, IL-8, IL-18 and VEGF). The remaining authors declare no competing interests.

17

18 REFERENCES

- 19 [1] J. Yang, K. Wang, H. Xu, W. Yan, Q. Jin, D. Cui, *Talanta* **2019**, 202, 96.
20 [2] X. Li, Y. Zhang, B. Xue, X. Kong, X. Liu, L. Tu, Y. Chang, H. Zhang, *Biosensors and Bioelectronics*
21 **2017**, 92, 517.
22 [3] Y. Rosenberg-Hasson, L. Hansmann, M. Liedtke, I. Herschmann, H. T. Maecker, *Immunologic*
23 *research* **2014**, 58, 224.
24 [4] a) A. Kaushik, M. A. Mujawar, Vol. 18, Multidisciplinary Digital Publishing Institute, 2018, 4303;
25 b) K. S. Prasad, X. Cao, N. Gao, Q. Jin, S. T. Sanjay, G. Henao-Pabon, X. Li, *Sensors and Actuators*
26 *B: Chemical* **2020**, 305, 127516; c) C. Dincer, R. Bruch, A. Kling, P. S. Dittrich, G. A. Urban, *Trends*
27 *in biotechnology* **2017**, 35, 728.
28 [5] S. S. Timilsina, P. Jolly, N. Durr, M. Yafia, D. E. Ingber, *Accounts of Chemical Research* **2021**, 54,
29 3529.
30 [6] a) N. Arroyo-Currás, P. Dauphin-Ducharme, K. Scida, J. L. Chávez, *Analytical Methods* **2020**, 12,
31 1288; b) S. Campuzano, M. Pedrero, M. Gamella, V. Serafín, P. Yáñez-Sedeño, J. M. Pingarrón,
32 *Sensors* **2020**, 20, 3376.
33 [7] U. Zupančič, P. Jolly, P. Estrela, D. Moschou, D. E. Ingber, *Advanced Functional Materials* **2021**,
34 31, 2010638.

- 1 [8] a) S. S. Timilsina, N. Durr, M. Yafia, H. Sallum, P. Jolly, D. E. Ingber, *Advanced healthcare*
2 *materials* **2021**, e2102244; b) J. Sabaté del Río, O. Y. Henry, P. Jolly, D. E. Ingber, *Nature*
3 *nanotechnology* **2019**, 14, 1143.
- 4 [9] a) S. T. Sanjay, M. Dou, J. Sun, X. Li, *Scientific reports* **2016**, 6, 1; b) M. Dou, S. T. Sanjay, D. C.
5 Dominguez, S. Zhan, X. Li, *Chemical communications* **2017**, 53, 10886; c) X. Wei, W. Zhou, S. T.
6 Sanjay, J. Zhang, Q. Jin, F. Xu, D. C. Dominguez, X. Li, *Analytical chemistry* **2018**, 90, 9888.
- 7 [10] I. Taneja, G. L. Damhorst, C. Lopez - Espina, S. D. Zhao, R. Zhu, S. Khan, K. White, J. Kumar, A.
8 Vincent, L. Yeh, *Clinical and translational science* **2021**, 14, 1578.
- 9 [11] M. M. Ling, C. Ricks, P. Lea, *Expert review of molecular diagnostics* **2007**, 7, 87.
- 10 [12] N. Madaboosi, R. R. Soares, V. Chu, J. P. Conde, *Analyst* **2015**, 140, 4423.
- 11 [13] a) M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, J. C. Burnett,
12 *Journal of the American College of Cardiology* **2002**, 40, 976; b) T. Mueller, M. Egger, E. Peer, E.
13 Jani, B. Dieplinger, *Clinica Chimica Acta* **2018**, 487, 66.
- 14 [14] D. C. Malaspina, G. Longo, I. Szeleifer, *PLoS One* **2017**, 12, e0185518.
- 15 [15] R. Ahmad, L. Xie, M. Pyle, M. F. Suarez, T. Broger, D. Steinberg, S. M. Ame, M. G. Lucero, M. J.
16 Szucs, M. MacMullan, *Science translational medicine* **2019**, 11, eaaw8287.
- 17 [16] C. T. Turner, R. K. Gupta, E. Tsaliki, J. K. Roe, P. Mondal, G. R. Nyawo, Z. Palmer, R. F. Miller, B.
18 W. Reeve, G. Theron, *The Lancet Respiratory Medicine* **2020**, 8, 407.
- 19 [17] a) J. Dinulos, *Habif's Clinical Dermatology. 7th ed. Philadelphia, PA: Elsevier* **2021**; b) N. I.
20 Rashwan, M. H. Hassan, Z. M. M. El-Deen, A. El-Abd Ahmed, *Pediatrics & Neonatology* **2019**, 60,
21 149.
- 22 [18] a) K. N. Varhaug, Ø. Torkildsen, K.-M. Myhr, C. A. Vedeler, *Frontiers in neurology* **2019**, 10, 338;
23 b) N. Siller, J. Kuhle, M. Muthuraman, C. Barro, T. Uphaus, S. Groppa, L. Kappos, F. Zipp, S.
24 Bittner, *Multiple Sclerosis Journal* **2019**, 25, 678.
- 25 [19] J. Tate, G. Ward, *The clinical biochemist reviews* **2004**, 25, 105.
- 26 [20] M. L. Chiu, W. Lawi, S. T. Snyder, P. K. Wong, J. C. Liao, V. Gau, *JALA: Journal of the Association*
27 *for Laboratory Automation* **2010**, 15, 233.
- 28 [21] M. A. Johansson, K.-E. Hellenäs, *Analyst* **2004**, 129, 438.
- 29 [22] J. Sun, Y. Liu, *Micromachines* **2018**, 9, 142.
- 30 [23] a) P. Denniff, N. Spooner, *Bioanalysis* **2010**, 2, 1385; b) G. N. Eick, P. Kowal, T. Barrett, E. A.
31 Thiele, J. J. Snodgrass, *Biodemography and Social Biology* **2017**, 63, 116.
- 32 [24] A. MacNeil, P. Glaziou, C. Sismanidis, A. Date, S. Maloney, K. Floyd, *Morbidity and Mortality*
33 *Weekly Report* **2020**, 69, 281.
- 34 [25] K. Dheda, M. Ruhwald, G. Theron, J. Peter, W. C. Yam, *Respirology* **2013**, 18, 217.

35

36

37

38


39

40

41

1

2 **TOC figure:**



3

4

5